Focus on Asthma Care

Back to articles

Persistent Asthma: Combination Therapy Supported by New Studies

KEY POINT

While not an overt departure from current national guidelines, several recent studies support a greater use of combination therapy for patients with persistent asthma. New approaches tend to combine other long-term control therapies with lower or more moderate doses of inhaled corticosteroids than those in current NIH guidelines.

SOURCES

Lazarus SC et al. Long-acting β2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001;265:2583–93.

Lemanske RF Jr. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA. 2001;285:2594–603.

Holgate ST. Therapeutic options for persistent asthma [editorial]. JAMA. 2001;285:2637–9.

Cloosterman SGM et al. A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting β2-agonists in allergic asthmatic patients. Chest. 2001;119:1306–15.

Blais R et al. Ambulatory use of inhaled β2-agonists for the treatment of asthma in Quebec: a population-based utilization review. Chest. 2001;119:1316–21.